Could a menopause drug ease schizophrenia symptoms in women?

NCT ID NCT04113993

Recruiting now Symptom relief Sponsor: The Alfred Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether bazedoxifene, a drug that mimics estrogen, can help reduce schizophrenia symptoms in women when added to their usual antipsychotic medication. 160 women aged 18-65 with schizophrenia or related disorders will receive either bazedoxifene or a placebo daily for 12 weeks. The goal is to see if it improves psychotic symptoms and thinking abilities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bazedoxifene Acetate
What this could lead to: If it works, this could offer a new way to reduce schizophrenia symptoms in women by adding bazedoxifene to their regular antipsychotic medication.
What could go wrong: This is a relatively small, early-phase trial. The drug may not improve symptoms more than placebo, and side effects from the hormone modulator are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZO AFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZO AFFECTIVE DISORDER SCHIZOPHRENIA SCHIZOPHRENIFORM DISORDERS

Contacts and locations

Locations

Multidisciplinary Alfred Psychiatry Research Centre
RECRUITING

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.